Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grifols To Divest Factor VIII Product Koate To Merge With Talecris

This article was originally published in The Pink Sheet Daily

Executive Summary

Italian company Kedrion will get the Factor VIII product Koate and a fractionation facility in Melville, N.Y., under a consent agreement with the Federal Trade Commission.

You may also be interested in...



Analysts Mixed As Australia’s CSL Moves To Settle U.S. Price Fixing Case

Australia’s CSL has probably made the right decision to settle a price-fixing lawsuit in the United States and thereby avoid a protracted legal battle that could have seen further substantial legal costs even if it eventually won. But the proposed settlement has some analysts concerned the legal basis for the lawsuit was thin as it stemmed from regulatory questions raised in a failed industry merger.

Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon

FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.

Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon

FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.

Related Content

Topics

UsernamePublicRestriction

Register

PS072267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel